Cox John

CEO John Cox bought 100,000 DYN shares at $9.11; stock now $8.28, down 42.5% in 30 days, while his prior 5 DYN buys posted 0% 90-day win rate.

CEO John Cox purchased 100,000 shares of Dyne Therapeutics at $9.11 on 2025-07-14, increasing his holdings by 97.9% to 202,179 shares. The stock has declined significantly since the purchase: it is currently priced at $8.28, down 42.5% over the past 30 days and 82.4% below its 52-week high of $47.04. Of greater concern is the timing pattern: Cox's prior 5 buys at DYN, all executed on 2024-09-04, produced a 0% win rate at the 90-day mark, with post-purchase returns ranging from -13.5% to -14.9%. His cross-ticker open-market track record shows 8 prior buys with a 0.00% 90-day win rate and an average 90-day return of -14.2%, suggesting a persistent pattern of unfavorable entry timing across his insider trading activity. The company remains unprofitable with a net income of $-115.4M and a market cap of $941.2M, adding fundamental headwinds to the technical deterioration.

DYN CEO Cox purchases 32,000 shares for $1.1M across 8 transactions on 2024-09-04, at blended average $33.04.

Cox John, CEO & President, executed 8 separate purchases totaling 32,000 shares for $1,057,216.00 on 2024-09-04, at a blended average price of $33.04 per share. This represents a substantial absolute dollar commitment from the company's chief executive. The company is unprofitable with net income of $-65,102,000.00 over its most recent fiscal year, and the stock has declined 28.2% from its 52-week high of $47.04. The post-transaction holding of 8,000 shares follows a pre-transaction position of -24,000 shares, indicating the purchase fully resolved a net short position into a net long position of 8.0K shares. While the magnitude of the purchase and the shift from negative to positive ownership are noteworthy, the execution at prices already 18.1% below the 30-day average against an unprofitable company backdrop warrants investor scrutiny of the underlying context.